DayTwo

Company Overview

Snapshot

Founded in August 2015 by Lihi Segal and Marius Nacht, DayTwo operates with 11–50 employees. The company has raised a total of $90 million across 7 funding rounds from 11 investors. In July 2023, DayTwo ceased most of its operations.

Business overview

DayTwo is a health tech company focused on precision nutrition for chronic conditions such as diabetes, prediabetes, and clinical obesity. The company utilizes high-resolution microbiome analysis and an AI-based algorithm to predict individual blood sugar responses to various foods. Its clinically proven approach is built upon one of the world's largest proprietary microbiome datasets, serving markets in the United States, North America, and Israel.

Strategic signal

In July 2023, DayTwo ceased most of its operations, marking a significant downturn for the healthtech startup. This event signals a challenging period for the company, indicating a failure to meet its initial promise despite substantial funding and a focus on a critical area of health innovation.

Company Intelligence Q&A

What is DayTwo's primary focus?

DayTwo specializes in precision nutrition, developing individualized solutions for chronic conditions like diabetes, prediabetes, and clinical obesity, leveraging microbiome analysis.

When did DayTwo cease most of its operations?

DayTwo ceased most of its operations in July 2023.

What was the total capital raised by DayTwo?

DayTwo raised a total of $90 million across 7 funding rounds.

Which investors participated in DayTwo's October 2019 funding round?

In October 2019, DayTwo received funding from Longliv Ventures and Samsung Next TLV.